Published in Cardiovascular Week, November 3rd, 2003
The action will affect customers in the United States, Europe, and Australia.
Working with the U.S. Food and Drug Administration and other regulatory bodies, Guidant has taken action to address this matter and is currently shipping 3.0 mm-diameter Multi-Link Vision stents to customers worldwide.
Patients who have received the Multi-Link Vision stent are not affected by this action. The safety and effectiveness of the implanted product is supported by positive long-term clinical data....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
Source: Cardiovascular Week (2003-11-03)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.